Table 5.
Adverse effects
| 3 Months Prednisolone | 6 Months Prednisolone | P Value | |
|---|---|---|---|
| BP≥P95 | |||
| At diagnosis | 36/61 (59%) | 28/62 (45%) | 0.15 |
| At 3 months FU | 12/57 (21%) | 7/60 (12%) | 0.21 |
| At 6 months FU | 8/55 (14%) | 10/52 (19%) | 0.61 |
| Cushingoid appearance at 6 months FU | |||
| Cushing (moon face) | 14/59 (23.7%) | 21/58 (36.2%) | 0.14 |
| Striae | 3/58 (5.2%) | 4/60 (6.7%) | 1.00 |
| Ophtalmological abnormalities at 6 months FU | |||
| Glaucoma | 0/51 (0.0%) | 0/45 (0.0%) | — |
| Cataract | 1/53(1.9%)a | 0/46 (0.0%) | 1.00 |
| Severe infections | |||
| Pneumonia | 1/62 (1.6%) | 6/64 (9.4%) | 0.16 |
| Meningitis | 0/62 (0.0%) | 0/64 (0.0%) | — |
| Osteomyelitis | 0/62 (0.0%) | 0/64 (0.0%) | — |
| VZV reactivation | 2/62 (3.2%) | 1/64 (1.6%) | 0.62 |
| Whooping cough | 0/62 (0.0%) | 2/64 (3.1%) | 0.50 |
| Miscellaneousb | 3/62 (4.8%) | 1/64 (1.6%) | 0.36 |
| Overall | 6/62 (9.7%) | 10/64 (15.6%) | 0.42 |
| Dyspepsia | 1/62 (1.6%) | 2/64 (3.1%) | 1.00 |
| Thrombosis | 0/62 (0.0%) | 0/64 (0.0%) | — |
Data are expressed as number of events/number analyzed (percentages). FU, follow-up; VZV, Varicella Zoster virus.
a
Mild cataract, which was absent at diagnosis.
b
Three-month group: n=1 cellulitis, n=1 muscle abscess, n=1 intracranial abscess. Six-month group: n=1 appendicitis.